Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Price-to-Free-Cash-Flow : 21.63 (As of Apr. 30, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-04-30), Clinuvel Pharmaceuticals's share price is $9.995. Clinuvel Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.46. Hence, Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 21.63.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

CLVLF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 19.25 Med: 60.68 Max: 164.04
Current: 21.47

During the past 13 years, Clinuvel Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 164.04. The lowest was 19.25. And the median was 60.68.

CLVLF's Price-to-Free-Cash-Flow is ranked better than
60.85% of 212 companies
in the Biotechnology industry
Industry Median: 30.61 vs CLVLF: 21.47

Clinuvel Pharmaceuticals's Free Cash Flow per Share for the six months ended in Dec. 2023 was $0.27. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.46.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Clinuvel Pharmaceuticals was -17.90% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 37.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 25.30% per year.

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 37.90% per year. The lowest was -85.30% per year. And the median was 15.30% per year.

Clinuvel Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Price-to-Free-Cash-Flow Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Free-Cash-Flow

Get a 7-Day Free Trial

91.77

97.16

85.28

19.51

25.80

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Free-Cash-Flow	Get a 7-Day Free Trial															-	19.51	-	25.80	-

Competitive Comparison of Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow falls into.

Clinuvel Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	9.995	/	0.462
	=	21.63

Clinuvel Pharmaceuticals's Share Price of today is $9.995.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.46.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Clinuvel Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.